Mohamad Mohty – VJRegenMed

CAR-T in myeloma: key players in the therapeutic landscape

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses CAR T-cell therapy for multiple myeloma. Although the multiple myeloma treatment landscape is rapidly evolving and the development of new therapies has greatly improved outcomes, patients with triple or penta-refractory disease still have limited treatment options. Recently, clinical trials investigating CAR T-cells for multiple myeloma have demonstrated promising clinical activity, showing unprecedented response rates in these heavily pre-treated patient population. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are among several BCMA CAR T-cell products in later stages of clinical trials, and it is anticipated that they will be approved in 2021. Prof. Mohty believes that the whole treatment paradigm will see some significant changes in the next five years as CAR T-cells move into earlier lines of therapy. Additionally, Prof. Mohty highlights other immunotherapy strategies, such as BiTEs, as well as novel targets. This interview took place during the 3rd European CAR T-cell Meeting.

The value of real-world data in the CAR-T field

Marta Palhas — Fri, 26 Feb 2021 14:08:23 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the value of real-world data in the field of CAR T-cell therapies. Real-world data can provide much-added value and information compared with prospective data. Particularly in the CAR-T field, the multitude of different stakeholders requires additional, comprehensive information, including effectiveness in larger real-world populations. Therefore, real-world evidence can complement data from clinical trials to help inform clinicians, patients, regulatory agencies, and payers. Additionally, Prof. Mohty highlights how real-world data will help develop non only the CAR-T field but also cellular therapy in general. This interview took place during the 3rd European CAR T-cell Meeting.

An overview of the CAR T-cell therapy story

Marta Palhas — Fri, 26 Feb 2021 14:08:22 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an overview of the CAR T-cell therapy story so far. The introduction of CAR T-cell therapy was a real revolution in the field of hematology. Following the breakthrough clinical results in the pivotal trials, the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have approved two anti-CD19 CAR T-cell products: tisagenlecleucel for the use in children and young adults up to 25 years of age with relapsed/refractory (R/R) acute lymphoblastic leukemia, and tisagenlecleucel and axicabtagene ciloleucel for the use in adult patients with R/R diffuse large B-cell lymphoma. In addition, several clinical trials are currently investigating the use of CAR T-cells in other hematological malignancies. It is anticipated that other CAR T-cell products will soon be approved. This interview took place during the 3rd European CAR T-cell Meeting.